Sandra Misale

List of Publications by Year
in descending order

22 papers	4,438 citations	361413 20 h-index	677142 22 g-index
22 all docs	22 docs citations	22 times ranked	7606 citing authors

#	Article	IF	Citations
1	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012, 486, 532-536.	27.8	1,605
2	Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discovery, 2014, 4, 1269-1280.	9.4	415
3	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer Discovery, 2016, 6, 36-44.	9.4	258
4	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discovery, 2020, 10, 1129-1139.	9.4	245
5	Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. Science Translational Medicine, 2014, 6, 224ra26.	12.4	228
6	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clinical Cancer Research, 2015, 21, 2157-2166.	7.0	227
7	KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Clinical Cancer Research, 2019, 25, 796-807.	7.0	175
8	KRAS gene amplification in colorectal cancer and impact on response to EGFRâ€targeted therapy. International Journal of Cancer, 2013, 133, 1259-1265.	5.1	154
9	HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	9.4	149
10	Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature, 2019, 570, 112-116.	27.8	147
11	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine, 2019, 25, 1422-1427.	30.7	144
12	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	111
13	Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discovery, 2022, 12, 924-937.	9.4	110
14	TGFÎ± and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells. Clinical Cancer Research, 2014, 20, 6429-6438.	7.0	101
15	Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nature Communications, 2015, 6, 8305.	12.8	97
16	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Science Translational Medicine, 2016, 8, 324ra14.	12.4	81
17	STAT3 can serve as a hit in the process of malignant transformation of primary cells. Cell Death and Differentiation, 2012, 19, 1390-1397.	11.2	57
18	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	27.8	44

#	Article	IF	Citations
19	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discovery, 2021, 11, 126-141.	9.4	34
20	Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene, 2018, 37, 4599-4610.	5.9	30
21	KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 2604-2612.	7.0	20
22	Resistance is futile with fourth-generation EGFR inhibitors. Nature Cancer, 2022, 3, 381-383.	13.2	6